Registration Dossier

Administrative data

Workers - Hazard via inhalation route

Systemic effects

Long term exposure
Hazard assessment conclusion:
DNEL (Derived No Effect Level)
Value:
11.75 mg/m³
Most sensitive endpoint:
repeated dose toxicity
Route of original study:
Oral
DNEL related information
DNEL derivation method:
ECHA REACH Guidance
Overall assessment factor (AF):
150
Modified dose descriptor starting point:
NOAEC
DNEL value:
1 763.2 mg/m³
Explanation for the modification of the dose descriptor starting point:
No study on long-term inhalation toxicity available
AF for dose response relationship:
1
Justification:
The dose descriptor starting point is based on a NOAEL.
AF for differences in duration of exposure:
6
Justification:
Subacute (28-day repeated dose study) to chronic
AF for interspecies differences (allometric scaling):
1
Justification:
AF not used for inhalation route.
AF for other interspecies differences:
2.5
Justification:
Default value according to ECHA REACH Guidance.
AF for intraspecies differences:
5
Justification:
Default value for workers according to ECHA REACH Guidance.
AF for the quality of the whole database:
2
Justification:
Remaining uncertainties due to data waiving for toxicity to reproduction.
AF for remaining uncertainties:
1
Justification:
No further remaining uncertainties.
Acute/short term exposure
Hazard assessment conclusion:
hazard unknown (no further information necessary)
DNEL related information

Local effects

Long term exposure
Hazard assessment conclusion:
hazard unknown (no further information necessary)
Acute/short term exposure
Hazard assessment conclusion:
hazard unknown (no further information necessary)
DNEL related information

Workers - Hazard via dermal route

Systemic effects

Long term exposure
Hazard assessment conclusion:
DNEL (Derived No Effect Level)
Value:
1.67 mg/kg bw/day
Most sensitive endpoint:
repeated dose toxicity
Route of original study:
Oral
DNEL related information
DNEL derivation method:
ECHA REACH Guidance
Overall assessment factor (AF):
600
Modified dose descriptor starting point:
NOAEL
DNEL value:
1 000 mg/kg bw/day
Explanation for the modification of the dose descriptor starting point:
No study on long-term dermal toxicity available
AF for dose response relationship:
1
Justification:
The dose descriptor starting point is based on a NOAEL.
AF for differences in duration of exposure:
6
Justification:
subacute (28-day repeated dose study) to chronic
AF for interspecies differences (allometric scaling):
4
Justification:
The experimental animal was the rat.
AF for other interspecies differences:
2.5
Justification:
Default value according to ECHA REACH Guidance.
AF for intraspecies differences:
5
Justification:
Default value according to ECHA REACH Guidance.
AF for the quality of the whole database:
2
Justification:
Remaining uncertainties due to data waiving for toxicity to reproduction.
AF for remaining uncertainties:
1
Justification:
No further remaining unceratainties.
Acute/short term exposure
Hazard assessment conclusion:
no hazard identified
DNEL related information

Local effects

Long term exposure
Hazard assessment conclusion:
hazard unknown (no further information necessary)
Acute/short term exposure
Hazard assessment conclusion:
no hazard identified

Workers - Hazard for the eyes

Local effects

Hazard assessment conclusion:
no hazard identified

Additional information - workers

No DNELs have been derived for systemic effects after short-term exposure of 2 -methyl-N-(4 -sulfamoylphenyl) prop-2 -enamide (SPM-N) for workers, as it is assumed that the assessment of hazard is sufficiently covered by deriving the respective DNELs for long-term exposure. In addition, no DNEL has been derived for short-term dermal and inhalation exposure, since no hazard was identified. Moreover, SPM-N was not skin or eye irritating, nor skin sensitising (Stitzinger, 2008c,d,e). 

The long-term worker DNEL for dermal systemic effects is based on the 28-day repeated dose toxicity study (van Otterdijk, 2008) performed according to OECD Guideline 407 in rats with test substance concentrations of 50, 150 and 1000 mg/kg bw/day. No animals died and no effects with toxicological relevance were observed on body weights, organ weights, haematologic and clinical chemistry parameters in the study. The gross and histopathologic examinations did not show treatment-related effects. As no effects were observed up to and including the highest dose level, the NOAEL is ≥ 1000 mg/kg bw/day.

This NOAEL was chosen as the starting point for deriving the DNEL as there is no dermal repeated dose study available. To convert the oral NOAEL [mg/kg bw/day] into a dermal NOAEL [mg/kg bw/day], the differences in absorption between routes as well as differences in dermal absorption between rats and humans have to be accounted for (Guidance on information requirements and chemical safety assessment. Chapter R.8: Characterisation of dose [concentration]-response for human health, European Chemicals Agency, November 2012). For SPM-N, the oral bioavailability was predicted to be limited due to the low water solubility and the dermal absorption was considered to be very low (refer to Toxicokinetics, metabolism and distribution). As no quantitative information is available, no differences in absorption between the oral and dermal route were taken into account. Thus, a worst-case approach was considered for the dermal route as, in general, dermal absorption will not be higher than oral absorption.

The long-term worker DNEL for inhalation systemic effects is based on the 28-day repeated dose toxicity study performed according to OECD Guideline 407 in rats (van Otterdijk, 2008). This study was chosen as the starting point for deriving the DNEL as there is no inhalation repeated dose study available. According to the “Guidance on information requirements and chemical safety assessment. Chapter R.8: Characterisation of dose [concentration]-response for human health” (European Chemicals Agency, November 2012), the oral NOAEL should be converted into an inhalatory NOAEC: the oral dose for the rat is converted to the corresponding air concentration using a standard breathing volume for the rat (0.38 m³/kg for 8 h exposure). Additionally, it should be taken into account that during 8 hours light activity at work the respiratory rate becomes higher (10 m³/person) than standard (6.7 m³/person). Considering these differences, the correct starting point is a NOAEC of 1763.2 mg/m³. Based on the low water solubility, absorption of SPM-N via the oral and inhalation route is considered limited (refer to Toxicokinetics, metabolism and distribution). Therefore, it is assumed, that the inhalation absorption rate is in the same order of magnitude as the oral absorption. Moreover, only a very small fraction (< 0.8% by weight) of the non-dusting powder is inhalable (MMAD < 100 µm).

 

In general, AFs recommended by ECHA (Guidance on information requirements and chemical safety assessment. Chapter R.8: Characterisation of dose[concentration]-response for human health. European Chemicals Agency, November 2012) were used when applicable to derive the DNELs.

General Population - Hazard via inhalation route

Systemic effects

Long term exposure
Hazard assessment conclusion:
DNEL (Derived No Effect Level)
Value:
2.9 mg/m³
Most sensitive endpoint:
repeated dose toxicity
Route of original study:
Oral
DNEL related information
DNEL derivation method:
ECHA REACH Guidance
Overall assessment factor (AF):
300
Modified dose descriptor starting point:
NOAEC
DNEL value:
869.6 mg/m³
Explanation for the modification of the dose descriptor starting point:
No study on long-term inhalation toxicity available
AF for dose response relationship:
1
Justification:
The dose descriptor starting point is based on a NOAEL.
AF for differences in duration of exposure:
6
Justification:
subacute (28-day repeated dose study) to chronic
AF for interspecies differences (allometric scaling):
1
Justification:
AF not used for inhalation route.
AF for other interspecies differences:
2.5
Justification:
Default value according to ECHA REACH Guidance.
AF for intraspecies differences:
10
Justification:
Default value for general population according to ECHA REACH Guidance.
AF for the quality of the whole database:
2
Justification:
Remaining uncertainties due to data waiving for toxicity to reproduction.
AF for remaining uncertainties:
1
Justification:
No further remaining uncertainties.
Acute/short term exposure
Hazard assessment conclusion:
hazard unknown (no further information necessary)
DNEL related information

Local effects

Long term exposure
Hazard assessment conclusion:
hazard unknown (no further information necessary)
Acute/short term exposure
Hazard assessment conclusion:
hazard unknown (no further information necessary)
DNEL related information

General Population - Hazard via dermal route

Systemic effects

Long term exposure
Hazard assessment conclusion:
DNEL (Derived No Effect Level)
Value:
0.83 mg/kg bw/day
Most sensitive endpoint:
repeated dose toxicity
Route of original study:
Oral
DNEL related information
DNEL derivation method:
ECHA REACH Guidance
Overall assessment factor (AF):
1 200
Modified dose descriptor starting point:
NOAEL
DNEL value:
1 000 mg/kg bw/day
Explanation for the modification of the dose descriptor starting point:
No study on long-term dermal toxicity available
AF for dose response relationship:
1
Justification:
The dose descriptor starting point is based on a NOAEL.
AF for differences in duration of exposure:
6
Justification:
subacute (28-day repeated dose study) to chronic
AF for interspecies differences (allometric scaling):
4
Justification:
The experimental animal was the rat.
AF for other interspecies differences:
2.5
Justification:
Default value according to ECHA REACH Guidance.
AF for intraspecies differences:
10
Justification:
Default value for general population according to ECHA REACH Guidance.
AF for the quality of the whole database:
2
Justification:
Remaining uncertainties due to data waiving for toxicity to reproduction.
AF for remaining uncertainties:
1
Justification:
No further remaining uncertainties.
Acute/short term exposure
Hazard assessment conclusion:
no hazard identified
DNEL related information

Local effects

Long term exposure
Hazard assessment conclusion:
hazard unknown (no further information necessary)
Acute/short term exposure
Hazard assessment conclusion:
no hazard identified

General Population - Hazard via oral route

Systemic effects

Long term exposure
Hazard assessment conclusion:
DNEL (Derived No Effect Level)
Value:
0.83 mg/kg bw/day
Most sensitive endpoint:
repeated dose toxicity
Route of original study:
Oral
DNEL related information
DNEL derivation method:
ECHA REACH Guidance
Overall assessment factor (AF):
1 200
Modified dose descriptor starting point:
NOAEL
DNEL value:
1 000 mg/kg bw/day
Explanation for the modification of the dose descriptor starting point:
No route-to-route extrapolation required
AF for dose response relationship:
1
Justification:
The dose descriptor starting point is based on a NOAEL.
AF for differences in duration of exposure:
6
Justification:
subacute (28-day repeated dose study) to chronic
AF for interspecies differences (allometric scaling):
4
Justification:
The experimental animal was the rat.
AF for other interspecies differences:
2.5
Justification:
Default value according to ECHA REACH Guidance.
AF for intraspecies differences:
10
Justification:
Default value for general population according to ECHA REACH Guidance.
AF for the quality of the whole database:
2
Justification:
Remaining uncertainties due to data waiving for toxicity to reproduction.
AF for remaining uncertainties:
1
Justification:
No further remaining uncertainties.
Acute/short term exposure
Hazard assessment conclusion:
no hazard identified
DNEL related information

General Population - Hazard for the eyes

Local effects

Hazard assessment conclusion:
no hazard identified

Additional information - General Population

The general population is not exposed to 2 -methyl-N-(4 -sulfamoylphenyl) prop-2-enamide (SPM-N), based on its identified uses. However, the long-term consumer DNELs for oral, dermal and inhalation systemic effects have been derived.

No DNELs have been derived for systemic effects after short-term exposure of 2 -methyl-N-(4 -sulfamoylphenyl) prop-2-enamide (SPM-N) for the general population, as it is assumed that the assessment of hazard is sufficiently covered by deriving the respective DNELs for long-term exposure or since no hazard was identified based on experimental data, respectively.

Moreover, SPM-N was not skin or eye irritating, nor skin sensitising (Stitzinger, 2008c,d,e). 

The long-term DNEL for the general population in regard to dermal systemic effects is based on the 28-day repeated dose toxicity study (van Otterdijk, 2008) performed according to OECD Guideline 407 in rats with test substance concentrations of 50, 150 and 1000 mg/kg bw/day. No animals died and no effects with toxicological relevance were observed on body weights, organ weights, haematologic and clinical chemistry parameters in the study. The gross and histopathologic examinations did not show treatment-related effects. As no effects were observed up to and including the highest dose level, the NOAEL is ≥ 1000 mg/kg bw/day.

This NOAEL was chosen as the starting point for deriving the DNEL as there is no dermal repeated dose study available. To convert the oral NOAEL [mg/kg bw/day] into a dermal NOAEL [mg/kg bw/day], the differences in absorption between routes as well as differences in dermal absorption between rats and humans have to be accounted for (Guidance on information requirements and chemical safety assessment. Chapter R.8: Characterisation of dose [concentration]-response for human health, European Chemicals Agency, November 2012). For SPM-N, the oral bioavailability was predicted to be limited due to the low water solubility and the dermal absorption was considered to be very low (refer to Toxicokinetics, metabolism and distribution). As no quantitative information is available, no differences in absorption between the oral and dermal route were taken into account. Thus, a worst-case approach was considered for the dermal route as, in general, dermal absorption will not be higher than oral absorption.

The long-term DNEL for the general population in regard to systemic effects after inhalation exposure is based on the 28-day repeated dose toxicity study performed according to OECD Guideline 407 in rats (van Otterdijk, 2008). This study was chosen as the starting point for deriving the DNEL as there is no inhalation repeated dose study available. According to the “Guidance on information requirements and chemical safety assessment. Chapter R.8: Characterisation of dose [concentration]-response for human health” (European Chemicals Agency, November 2012), the oral NOAEL should be converted into an inhalatory NAEC: the oral dose for the rat is converted to the corresponding air concentration using a standard breathing volume for the rat (1.15 m³/kg for 24 h exposure). Therefore, the corrected starting point is a NAEC of 869.6 mg/m³.

Based on the low water solubility absorption of SPM-N via the oral and inhalation route is considered limited (refer to Toxicokinetics, metabolism and distribution). Therefore, it is assumed, that the inhalation absorption rate is in the same order of magnitude as the oral absorption. Moreover, only a very small fraction (< 0.8% by weight) of the non-dusting powder is inhalable (MMAD < 100 µm).

 

The long-term DNEL for the general population, oral systemic effects is also based on the 28-day repeated dose toxicity study (van Otterdijk, 2008), performed according to OECD Guideline 407 in rats. No toxicologically relevant effects were observed up to and including the highest dose level, therefore the NOAEL is considered to be ≥ 1000 mg/kg bw/day. The study was performed via the oral route and the value can be used directly to derive the oral DNEL.

In general, AFs recommended by ECHA (Guidance on information requirements and chemical safety assessment. Chapter R.8: Characterisation of dose[concentration]-response for human health. European Chemicals Agency, November 2012) were used when applicable to derive the DNELs.